Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
Baur, Francois; Beattie, David; Beer, David; Bentley, David; Bradley, Michelle; Bruce, Ian; Charlton, Steven J.; Cuenoud, Bernard; Ernst, Roland; Fairhurst, Robin A.; Faller, Bernard; Farr, David; Keller, Thomas; Fozard, John R.; Fullerton, Joe; Garman, Sheila; Hatto, Julia; Hayden, Claire; He, Handan; Howes, Colin; Janus, Diana; Jiang, Zhengjin; Lewis, Christine; Loeuillet-Ritzler, Frederique; Moser, Heinz; Reilly, John; Steward, Alan; Sykes, David; Tedaldi, Lauren; Trifilieff, Alexandre; Tweed, Morris; Watson, Simon; Wissler, Elke; Wyss, Daniel. The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist. Journal of Medicinal Chemistry. Volume 53. Issue 9. Pages 3675-3684. Journal. (2010).
Wang, Xiaoning; Liu, Fei; Zou, Yunfei. Method for preparing indacaterol maleate. Assignee Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Peop. Rep. China. CN 108250140. (2018).
Sunku, Venkataiah; Reddy, G. Pratap; Babu, Sunkaraneni Suresh. A process for preparing indacaterol and salts thereof. IN 2014MU02698. (2016).
Fu, Qingquan; Yue, Lijian; Lin, Qiang; Wang, Jian; Liu, Zhengchao; Zhao, Maoxian; Zhang, Yin. Method for synthesizing indacaterol. Assignee Chengdu D-Innovation Pharmaceutical Co., Ltd., Peop. Rep. China. CN 104744360. (2015).
Bonde-Larsen, Antonio Lorente; Sainz, Yolanda Fernandez; Retuerto, Jesus Iglesias; Nieto, Javier Gallo. Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof. Assignee Crystal Pharma S.A.U., Spain. WO 2014044566. (2014).
